Feasibility of a PB CD34(+) cell transplantation procedure using standard leukapheresis products in very small children

被引:24
作者
Berger, M
Kanold, J
Rapatel, C
deLumley, L
Lutz, P
Plantaz, D
Vannier, JP
Mechinaud, F
Bergeron, C
Favrot, M
Gembara, P
HalleHauss, P
Bonhomme, J
Travade, P
Demeocq, F
机构
[1] CHU, HOTEL DIEU, SERV PEDIAT B, SECTEUR ETUD HEMATOPOIESE, F-63000 CLERMONT FERRAND, FRANCE
[2] CHU, SERV PEDIAT B, UNITE BIOCLIN PRELEVEMENT & TRAITEMENT CELLULES S, F-63000 CLERMONT FERRAND, FRANCE
[3] HOP CHARLES NICOLLE, SERV PEDIAT & GENET MED, ROUEN, FRANCE
[4] HOP TRONCHE, DEPT MED & REANIMAT PEDIAT, GRENOBLE, FRANCE
[5] HOP UNIV DUPUYTREN, SERV PEDIAT 1, LIMOGES, FRANCE
[6] HOP CIVIL, SERV PEDIAT 1, STRASBOURG, FRANCE
[7] CTR LEON BERARD, UNITE FONCT GREFFE MEDULLAIRE, F-69373 LYON, FRANCE
[8] CHR, SERV ONCOL PEDIAT, NANTES, FRANCE
[9] CHR, SERV MED INFANTILE, RENNES, FRANCE
关键词
CD34 PBSC transplantation; children; neuroblastoma;
D O I
10.1038/sj.bmt.1700876
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
To evaluate the feasibility and efficacy of CD34(+) cell immunoselection from routine peripheral blood stem cell (PBSC) harvests in very small children a prospective study was performed in 15 children with advanced neuroblastoma weighing 20 kg or less, Products of two consecutive leukaphereses carried out on a COPE Spectra separator after G-CSF alone mobilization were pooled for immunoselection on Ceprate column, The median number of CD34(+) cells and total CFU-GM collected were respectively 5.9 x 10(6)/kg (range 2.3-23.4) and 126.9 x 10(4)/kg (range 52.9-559.9). After separation the median number of CD34(+) cells in the adsorbed fraction was 2.6 x 10(6)/kg (range 1-9.8) with a median purity of 54% (range 21-82) and a median of 95.7-fold (range 35-250) enrichment, Thirteen patients underwent autografts with CD34(+) PBSCs after a busulfan 600 mg/m(2) + melphalan 180 mg/m(2) preparative regimen, The median number of days to achieve an absolute granulocyte count of 0.5 x 10(9)/l and a platelet count of 20 x 10(9)/l were respectively, 12 (range 10-24) and 35 (range 25-43), The median number of platelet transfusions was nine (range 2-15). We conclude that safe and effective immunoselection and transplantation of CD34(+) PBSC can be accomplished in children with low body mass.
引用
收藏
页码:191 / 198
页数:8
相关论文
共 24 条
[1]  
ANDREWS RG, 1986, BLOOD, V67, P842
[2]  
BERENSON RJ, 1991, BLOOD, V77, P1717
[3]  
BERENSON RJ, 1989, AUTOLOGOUS BONE MARR, P55
[4]   INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA [J].
BRODEUR, GM ;
SEEGER, RC ;
BARRETT, A ;
BERTHOLD, F ;
CASTLEBERRY, RP ;
DANGIO, G ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
FREEMAN, AI ;
HAASE, G ;
HARTMANN, O ;
HAYES, FA ;
HELSON, L ;
KEMSHEAD, J ;
LAMPERT, F ;
NINANE, J ;
OHKAWA, H ;
PHILIP, T ;
PINKERTON, CR ;
PRITCHARD, J ;
SAWADA, T ;
SIEGEL, S ;
SMITH, EI ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) :1874-1881
[5]  
BRUGGER W, 1994, BLOOD, V83, P636
[6]   POSITIVELY SELECTED AUTOLOGOUS BLOOD CD34+ CELLS AND UNSEPARATED PERIPHERAL-BLOOD PROGENITOR CELLS MEDIATE IDENTICAL HEMATOPOIETIC ENGRAFTMENT AFTER HIGH-DOSE VP16, IFOSFAMIDE, CARBOPLATIN, AND EPIRUBICIN [J].
BRUGGER, W ;
HENSCHLER, R ;
HEIMFELD, S ;
BERENSON, RJ ;
MERTELSMANN, R ;
KANZ, L .
BLOOD, 1994, 84 (05) :1421-1426
[7]   NEUROBLASTOMA CELL DETECTION BY REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION (RT-PCR) FOR TYROSINE-HYDROXYLASE MESSENGER-RNA [J].
BURCHILL, SA ;
BRADBURY, FM ;
SMITH, B ;
LEWIS, IJ ;
SELBY, P .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (05) :671-675
[8]  
DEMEOCQ F, 1994, BONE MARROW TRANSPL, V13, P43
[9]   HISTOLOGICAL, CYTOLOGICAL AND IMMUNOLOGICAL ANALYSES ARE COMPLEMENTARY FOR THE DETECTION OF NEUROBLASTOMA-CELLS IN BONE-MARROW [J].
FAVROT, MC ;
FRAPPAZ, D ;
MARITAZ, O ;
PHILIP, I ;
FONTANIERE, B ;
GENTILHOMME, O ;
BAILLY, C ;
ZUCKER, JM ;
GENTET, JC ;
KEMSHEAD, J ;
PHILIP, T .
BRITISH JOURNAL OF CANCER, 1986, 54 (04) :637-641
[10]   PREPARATION AND SUCCESSFUL ENGRAFTMENT OF PURIFIED CD34(+) BONE-MARROW PROGENITOR CELLS IN PATIENTS WITH NON-HODGKINS-LYMPHOMA [J].
GORIN, NC ;
LOPEZ, M ;
LAPORTE, JP ;
QUITTET, P ;
LESAGE, S ;
LEMOINE, F ;
BERENSON, RJ ;
ISNARD, F ;
GRANDE, M ;
STACHOWIAK, J ;
LABOPIN, M ;
FOUILLARD, L ;
MOREL, P ;
JOUET, JP ;
NOELWALTER, MP ;
DETOURMIGNIES, L ;
AOUDJHANE, M ;
BAUTERS, F ;
NAJMAN, A ;
DOUAY, L .
BLOOD, 1995, 85 (06) :1647-1654